Cherubim Interests Stock (OTC:CHIT), Trade Ideas

Cherubim Interests Inc is a development stage company operates in real estate business. It focuses on alternative construction projects. The company specializes in covering the entire spectrum of development including due diligence, acquisition, planning, construction, renovation, and management; providing complete beginning-to-end development programs for mixed use, single, and multifamily projects and properties. Geographically, the activities are operated through the region of US.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABACUS HEALTH PRODUCTS by Abacus Health Products Inc

ABAHF

ACRGF

ADPT

AERO

ALBO

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AMCX

APTX

ASDN

ATADF

AVLIF

AVALON ADVANCED MAT ORD by Avalon Advanced Materials Inc.

AVLNF

AWSM

AWWC

BCEL

BICB

BIEI

BNGO

BTHCF

CBIIF

CDEV

CHFS

CLXT

CMMMF

CMRX

CNSL

CNXM

CPFXF

CRXPF

CTST

CVET

CYTR

DJIFF

DTIL

DZSI

EARS

EEVVF

ELCI

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

ENBL

ESTR

ETST

EWLL

FIXX

FRNKF

FTCH

FTSI

FTXP

GARWF

GAXY

GLAC

GOSS

GURE

HEXO

HIHO

HITIF

HREEF

HRVOF

HSDT

HZNOF

IAALF

ICUI

INAR

INDXF

INMB

INTV

ITHUF

IVITF

JAGX

JINFF

JMIA

KALA

KGET

KLXE

KNSA

KPAY

KRTX

LAIX

LBRT

LEMIF

LKCO

LMRXF

LOGX

LRTTF

MBVXQ

MIRM

MJARF

MJTV

MKRS

MNGGF

Stocks That Hit 52-Week Lows On Monday

CHERUBIM INTERESTS INC by Cherubim Interests, Inc.

Cherubim Interests Inc

ChitogenX Inc

<p>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) has outperformed the market over the past 5 years by 12.45% on an annualized basis producing an average annual return of 23.93%. Currently, First Solar has a market capitalization of $19.35 billion. </p>
<p><strong>Buying $100 In FSLR:</strong> If an investor had bought $100 of FSLR stock 5 years ago, it would be worth <strong>$293.73</strong> today based on a price of $180.76 for FSLR at the time of writing.</p>
<h3>First Solar's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898898_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FSLR

Here's How Much You Would Have Made Owning First Solar Stock In The Last 5 Years

<p>Ratings for Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.0, a high estimate of $40.00, and a low estimate of $24.00. This current average has increased by 26.87% from the previous average price target of $26.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898886_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Tandem Diabetes Care among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$24.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Tandem Diabetes Care's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Tandem Diabetes Care's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tandem Diabetes Care analyst ratings.</strong></a></p>
<h2>Get to Know Tandem Diabetes Care Better</h2>
<p>Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Unraveling the Financial Story of Tandem Diabetes Care</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-10.75%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-15.25%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-9.56%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Tandem Diabetes Care's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.17%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.33</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

TNDM

Cracking The Code: Understanding Analyst Reviews For Tandem Diabetes Care

<p>Over the past 24 hours, <strong>Aptos's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>) price has fallen 3.87% to <strong>$9.79</strong>. This is opposite to its positive trend over the past week where it has experienced a 8.0% gain, moving from $9.12 to its current price. </p>
<p>The chart below compares the price movement and volatility for Aptos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898875_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has tumbled 19.0% over the past week while the circulating supply of the coin has risen 0.93%. This brings the circulating supply to 426.02 million. According to our data, the current market cap ranking for APT is #28 at $4.16 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898875_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$APT

Cryptocurrency Aptos Down More Than 3% Within 24 hours

<p>Deep-pocketed investors have adopted a bearish approach towards Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CCJ usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Cameco. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 13% leaning bullish and 31% bearish. Among these notable options, 9 are puts, totaling $483,673, and 13 are calls, amounting to $1,667,990.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $70.0 for Cameco over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Cameco's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cameco's whale trades within a strike price range from $40.0 to $70.0 in the last 30 days. </p>
<h3>Cameco Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898861_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$2.3</td>
<td>$2.21</td>
<td>$2.25</td>
<td>$60.00</td>
<td>$1.1M</td>
<td>4.0K</td>
<td>5.0K</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$40.00</td>
<td>$145.1K</td>
<td>1.7K</td>
<td>1.1K</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$14.2</td>
<td>$14.0</td>
<td>$14.1</td>
<td>$60.00</td>
<td>$114.2K</td>
<td>429</td>
<td>162</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.4</td>
<td>$55.00</td>
<td>$76.5K</td>
<td>2.4K</td>
<td>255</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.75</td>
<td>$6.6</td>
<td>$6.7</td>
<td>$70.00</td>
<td>$67.0K</td>
<td>1.6K</td>
<td>367</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cameco</h3>
<p>Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.</p>
<p>In light of the recent options history for Cameco, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Cameco Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,666,157, the price of CCJ is up by 2.83%, reaching $48.63.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
<h3>Expert Opinions on Cameco</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $55.0.</p>
<ul>
<li>Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Buy with a new price target of $55.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cameco with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Unpacking the Latest Options Trading Trends in Cameco

<p>Financial giants have made a conspicuous bearish move on Analog Devices. Our analysis of options history for Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $183,718, and 5 were calls, valued at $231,119.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $210.0 for Analog Devices during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Analog Devices options trades today is 233.17 with a total volume of 1,472.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Analog Devices's big money trades within a strike price range of $165.0 to $210.0 over the last 30 days.</p>
<h3>Analog Devices Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898855_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ADI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.4</td>
<td>$9.9</td>
<td>$10.34</td>
<td>$165.00</td>
<td>$53.5K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">98</td>
</tr>
<tr>
<td>ADI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$195.00</td>
<td>$49.6K</td>
<td style="text-align: right;">346</td>
<td style="text-align: right;">470</td>
</tr>
<tr>
<td>ADI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$3.0</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$195.00</td>
<td>$46.5K</td>
<td style="text-align: right;">346</td>
<td style="text-align: right;">310</td>
</tr>
<tr>
<td>ADI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.8</td>
<td>$17.2</td>
<td>$17.67</td>
<td>$210.00</td>
<td>$46.1K</td>
<td style="text-align: right;">281</td>
<td style="text-align: right;">49</td>
</tr>
<tr>
<td>ADI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$2.95</td>
<td>$2.75</td>
<td>$2.9</td>
<td>$195.00</td>
<td>$44.6K</td>
<td style="text-align: right;">346</td>
<td style="text-align: right;">155</td>
</tr>
</tbody>
</table>
</p>
<h3>About Analog Devices</h3>
<p>Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.</p>
<p>Having examined the options trading patterns of Analog Devices, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Analog Devices</h3>
<ul>
<li>Trading volume stands at 1,684,241, with ADI's price up by 2.34%, positioned at $190.68.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 29 days.</li>
</ul>
<h3>Expert Opinions on Analog Devices</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $233.0.</p>
<ul>
<li>An analyst from Morgan Stanley persists with their Overweight rating on Analog Devices, maintaining a target price of $212. </li>
<li>An analyst from Evercore ISI Group has revised its rating downward to Outperform, adjusting the price target to $254. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Analog Devices options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With ADI

<p>Ratings for Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Vertex, presenting an average target of $38.3, a high estimate of $45.00, and a low estimate of $32.00. Surpassing the previous average price target of $31.78, the current average has increased by 20.52%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898851_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Vertex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$42.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Adam Hotchkiss</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$35.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vertex's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VERX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vertex analyst ratings.</strong></a></p>
<h2>About Vertex</h2>
<p>Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.</p>
<h3>Vertex's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Vertex's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>18.14%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Vertex's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.9%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Vertex's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.48%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.07%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Vertex's debt-to-equity ratio is below the industry average. With a ratio of <b>0.26</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VERX

Cracking The Code: Understanding Analyst Reviews For Vertex

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Qualcomm</strong>.</p>
<p>Looking at options history for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) we detected 70 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 38% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $1,164,630 and 53, calls, for a total amount of $5,656,812.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $220.0 for Qualcomm over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Qualcomm's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Qualcomm's significant trades, within a strike price range of $120.0 to $220.0, over the past month.</p>
<h3>Qualcomm 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898850_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$11.25</td>
<td>$11.1</td>
<td>$11.1</td>
<td>$155.00</td>
<td>$987.9K</td>
<td>8.6K</td>
<td>3.3K</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$14.9</td>
<td>$11.75</td>
<td>$12.89</td>
<td>$135.00</td>
<td>$451.1K</td>
<td>533</td>
<td>356</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$11.15</td>
<td>$11.05</td>
<td>$11.05</td>
<td>$155.00</td>
<td>$392.2K</td>
<td>8.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$11.05</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$155.00</td>
<td>$254.1K</td>
<td>8.6K</td>
<td>920</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$37.65</td>
<td>$37.0</td>
<td>$37.11</td>
<td>$150.00</td>
<td>$241.2K</td>
<td>1.4K</td>
<td>161</td>
</tr>
</tbody>
</table>
</p>
<h3>About Qualcomm</h3>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<p>Having examined the options trading patterns of Qualcomm, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Qualcomm's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,256,112, with QCOM's price up by 1.22%, positioned at $162.14.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 8 days.</li>
</ul>
<h3>Expert Opinions on Qualcomm</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $195.4.</p>
<ul>
<li>An analyst from Keybanc persists with their Overweight rating on Qualcomm, maintaining a target price of $205. </li>
<li>An analyst from Benchmark downgraded its action to Buy with a price target of $200. </li>
<li>An analyst from Cantor Fitzgerald persists with their Neutral rating on Qualcomm, maintaining a target price of $190. </li>
<li>An analyst from Susquehanna has decided to maintain their Positive rating on Qualcomm, which currently sits at a price target of $205. </li>
<li>An analyst from Evercore ISI Group has revised its rating downward to In-Line, adjusting the price target to $177. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


QCOM

What the Options Market Tells Us About Qualcomm

<p>7 analysts have shared their evaluations of Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.57, along with a high estimate of $50.00 and a low estimate of $16.00. This upward trend is apparent, with the current average reflecting a 12.54% increase from the previous average price target of $29.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898843_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Affirm Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Vincent Caintic</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$50.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Mike Burton</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Affirm Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Affirm Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Affirm Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Affirm Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AFRM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Affirm Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Affirm Holdings</h2>
<p>Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.</p>
<h3>Affirm Holdings: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Affirm Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>47.94%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-28.24%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Affirm Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-6.42%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Affirm Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.91%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Affirm Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.37</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AFRM

A Closer Look at 7 Analyst Recommendations For Affirm Holdings

<p>Ratings for Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $28.14, a high estimate of $30.00, and a low estimate of $26.00. A 6.73% drop is evident in the current average compared to the previous average price target of $30.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898834_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Intl Game Tech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>David Bain</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>John Staszak</td>
<td>Argus Research</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intl Game Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intl Game Tech compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Intl Game Tech's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Intl Game Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IGT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intl Game Tech analyst ratings.</strong></a></p>
<h2>About Intl Game Tech</h2>
<p>International Game Technology PLC is a gaming company that delivers entertaining and responsible gaming experiences for players across all channels. The company's operating segments include Global Lottery, Global Gaming, and PlayDigital. It generates maximum revenue from the Global Lottery segment. Global Lottery segment provides lottery products and services to governmental organizations through operating contracts, facilities management contracts, lottery management agreements, and product sales contracts. Geographically, it derives a majority of revenue from the United States.</p>
<h3>Intl Game Tech: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Intl Game Tech's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>3.39%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Intl Game Tech's net margin is impressive, surpassing industry averages. With a net margin of <strong>-0.71%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intl Game Tech's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-0.55%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Intl Game Tech's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.08%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>4.11</strong>, Intl Game Tech adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For Intl Game Tech

<p><strong>Moderna</strong>&nbsp;<strong>Inc.</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;is set&nbsp;to clash with&nbsp;<strong>Pfizer Inc.</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and&nbsp;<strong>BioNTech</strong>&nbsp;<strong>SE</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) in a pivotal London patent trial concerning the development of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38205528/declining-covid-19-vaccine-sales-pinches-moderna-pauses-kenya-vaccine-plant-plans" rel="noreferrer noopener">COVID-19 vaccines</a>.&nbsp;</p>
<p>The High Court is slated to address a legal complaint brought by Moderna. It alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development, a claim Pfizer and BioNTech have refuted by asserting patent invalidity.</p>
<p><strong><em>Related:</em></strong><em>&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38098422/arbutus-vs-moderna-patent-dispute-over-covid-19-vaccine-gets-response-from-judge" rel="noreferrer noopener">Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge</a>.</em></p>
<p>This legal showdown is part of a global series of intellectual property disputes revolving around mRNA technology.&nbsp;</p>
<p>This technology has been a revenue generator for the pharmaceutical industry, notably benefiting major players like Moderna, Pfizer, and BioNTech.&nbsp;</p>
<p>If&nbsp;successful, Moderna&nbsp;<a target="_blank" href="https://www.ft.com/content/41d9ec34-4bea-445f-98f4-27a20b9f4445" rel="noreferrer noopener">stands</a>&nbsp;to gain a portion of the profits derived from Pfizer and BioNTech&#8217;s joint vaccine, Comirnaty.&nbsp;</p>
<p>This could potentially influence similar litigations worldwide and enhance the reputations of the prevailing parties, the Financial Times notes.</p>
<p>Moderna&#8217;s lawsuit in London is not aimed at halting the use of the Pfizer/BioNTech vaccine but seeks acknowledgment of patent infringement and compensation.&nbsp;</p>
<p>With declining sales of its Spikevax product, Moderna eyes royalties from Comirnaty to offset losses.</p>
<p>The outcome of this legal battle extends beyond financial gains, potentially shaping the future landscape of mRNA-based products, particularly in areas like cancer treatment and autoimmune diseases.&nbsp;</p>
<p>While a verdict in the London case is pending, previous decisions have not uniformly favored Moderna, indicating prolonged litigation.&nbsp;</p>
<p>A parallel trial in May will delve into Moderna&#8217;s amendment of its intellectual property pledge, a move contested by Pfizer and BioNTech, underscoring the complexity and novelty of the legal dispute.&nbsp;</p>
<p><strong><em>Read Next:</em></strong><em>&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37941047/modernas-next-gen-covid-vaccine-meets-primary-goal-in-late-stage-trial" rel="noreferrer noopener">Moderna&#8217;s Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial</a>.</em></p>
<p><strong>Price Action:&nbsp;</strong>PFE shares are up 0.13% at $26.30, and&nbsp;MRNA stock is up 3.57% at $ 108.19 at the last check Tuesday.</p>
<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Photo via Wikimedia Commons</em></p>


Biotech

Large Cap

Health Care

Legal

BNTX

MRNA

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

<p>Throughout the last three months, 7 analysts have evaluated Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.5, along with a high estimate of $13.50 and a low estimate of $8.00. This current average has decreased by 3.65% from the previous average price target of $9.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898818_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Comstock Resources. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derrick Whitfield</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Comstock Resources. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Comstock Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Comstock Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Comstock Resources's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comstock Resources analyst ratings.</strong></a></p>
<h2>About Comstock Resources</h2>
<p>Comstock Resources Inc is an independent energy company operating in the Haynesville shale, a natural gas basin located in East Texas and North Louisiana with superior economics and geographical proximity to the Gulf Coast markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. Its oil and gas operations are concentrated in Louisiana and Texas.</p>
<h3>A Deep Dive into Comstock Resources's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Comstock Resources's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-55.49%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Comstock Resources's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>26.32%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Comstock Resources's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>4.66%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Comstock Resources's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.76%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Comstock Resources's debt-to-equity ratio surpasses industry norms, standing at <strong>1.15</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Comstock Resources

<p>Over the past 24 hours, <strong>Hedera's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>) price has risen 35.41% to <strong>$0.12</strong>. This continues its positive trend over the past week where it has experienced a 55.0% gain, moving from $0.08 to its current price. As it stands right now, <strong>the coin's all-time high is $0.57</strong>. </p>
<p>The chart below compares the price movement and volatility for Hedera over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898805_0.png" alt="price_chart" /></p>
<p>Hedera's trading volume has climbed 333.0% over the past week along with the circulating supply of the coin, which has increased 0.43%. This brings the circulating supply to 35.74 billion, which makes up an estimated 71.49% of its max supply of 50.00 billion. According to our data, the current market cap ranking for HBAR is #26 at $4.31 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713898805_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$HBAR

Cryptocurrency Hedera's Price Increased More Than 35% Within 24 hours

WIIM

DELL

Dell shares are trading higher amid strength in tech stocks. The company also said it is expanding its edge partner ecosystem with Hyundai AutoEver and Intel.

Management

RNST

Renasant Designates Kevin Chapman As CEO Of Company And Renasant Bank Effective May, 2025

<p>After a year with of layoffs and activist attention that triggered many changes, Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) managed to surpass both top and bottom estimates. Moreover, the streaming giant reported record first quarter earnings as the result of efficient cost-cutting initiatives that also brought significant margin improvements.&nbsp;</p>
<h3>First Quarter Financials Shows That A&nbsp;Shift In Focus Paid Off</h3>
<p>For the quarter ended in March, Spotify reported revenue rise 20% YoY to&nbsp;3.64 billion euros, surpassing LSEG&rsquo;s estimate of&nbsp;3.61 billion.&nbsp;</p>
<p>&nbsp;As a result of cost-cutting efforts that included layoffs, Spotify reported earnings of 97 euro cents&nbsp;which equate to $1.04, leaving LSEG&rsquo;s estimate of 65 euro cents far behind as gross margin&nbsp;reached 27.6%.</p>
<p>Spotify ended its fiscal first quarter with 615 million&nbsp;monthly active users, which was 3 million short of StreetAccount&rsquo;s estimate, but&nbsp;business grew as MAUs rose 19% YoY and 2% from the previous quarter. As part of cost-cutting measures, Spotify also lowered its marketing activity which also contributed to a more normalized growth.&nbsp;Spotify also grew its subscribers&nbsp;14% YoY to 239 million.</p>
<h3>Second Quarter Guidance</h3>
<p>For the current quarter, Spotify guided for net new MAUs of 16 million, which would bring the total of monthly active users to 631 million.&nbsp;With cost improvements across its business, the Swedish streaming company also forecasted its&nbsp;gross margin will improve to 28.1%.</p>
<h3>First Quarter Was A&nbsp;Victory For Spotify&nbsp;Across Many Fronts</h3>
<p>Shifting its focus on strengthening revenue growth and expanding the margin paid off. In addition, the EU sided with Spotify in its epic battle with Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) during the quarter. The EU punished Apple with a historic fine for distorting music streaming competition. Due to a complaint from Spotify, the EU already slapped Apple with an antitrust fine of $1.95 billion in March. This is a big victory for Spotify who started complaining back in&nbsp;2019 about Apple preventing music streaming services from informing users of payment options outside its App Store. Despite the fact Apple is a tech titan, when it comes to music streaming, Spotify is the dominant one. Fortunately for Spotify, EU regulators are ignoring its dominance and going after&nbsp;Apple instead.&nbsp;Therefore, Spotify had a record profit as well as an epic win during the first quarter that will undoubtedly go down in its history.&nbsp;</p>
<p><em>DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.</em></p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</em></p>


Entertainment

AAPL

SPOT

Spotify's First Quarter Tells A Story Of Record Profit And An Epic Win

U.S. Defense Contractor L3Harris To Cut 5% Of Its Workforce This Year In Cost-Saving Measure, Email Shows

<p><em>Editor&#8217;s Note: The headline for this article has been updated.</em></p>
<p>According to a new report, German media company <strong>Axel Springer</strong> is considering an acquisition of The Wall Street Journal, expanding its already significant presence in the United States. The company currently owns Insider, Politico, <a href="http://benzinga.com/m-a/21/08/22680278/axel-springer-acquires-politico-in-reported-1b-deal">and other media assets.</a></p>
<p><strong>What Happened</strong>: Axel Springer CEO <strong>Mathias Döpfner</strong> has plans to grow the publisher in the United States, which comes at a time when media companies are deciding the role artificial intelligence could play in the <a href="https://www.benzinga.com/markets/equities/23/12/36226257/openai-global-publisher-axel-springer-collaborate-to-train-genai-for-journalism-content-creation">future of journalism</a>.</p>
<p>A report from <a href="https://www.semafor.com/article/04/21/2024/axel-springers-trump-years">Semafor </a>links Axel Springer to interest in acquiring The Wall Street Journal.</p>
<p>Axel Springer recently opened a new headquarters in the United States, which could be a sign of its growing ambitions in the country. A 2023 Economist <a href="https://www.economist.com/business/2023/02/23/axel-springer-is-going-all-in-on-america">report </a>also pointed to the media company looking to increase its presence in the United States.</p>
<p>The company could also be looking to spin off assets in Europe, moves that would come as it boosts its U.S. presence, and also to bring a return on investment to <strong>KKR &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), which is the largest shareholder in the company.</p>
<p>Döpfner is also a key owner of around 22% of the company.</p>
<p>Reports of a larger U.S. presence comes as one of the company's key American assets (Insider)<a href="https://www.benzinga.com/news/24/01/36572896/bill-ackman-axel-springer-controversy-brews-business-insider-faces-editorial-review-over-accusations"> is in conflict </a>with leading American investor<strong> Bill Ackman.</strong></p>
<p>According to the report, Döpfner pushed to fire <strong>Nicholas Carlson</strong>, a Business Insider editor, over his coverage of Ackman's wife <strong>Neri Oxman</strong>.</p>
<p>The report indicates that while Axel Springer has publicly defended its coverage of Ackman's wife, private discussions indicate the company is considering some of Ackman's demands. The conversation centers on whether meeting Ackman&#8217;s conditions could circumvent a costly legal battle, with Ackman represented by the defamation law firm Clare Locke.</p>
<p>As the company pursues acquisitions in the U.S., the Ackman issue has the potential to divert significant time and financial resources, potentially impeding the company&#8217;s growth in America until the case is resolved.</p>
<p><em>Related Link: <a href="https://www.benzinga.com/news/24/01/36634863/business-insider-is-toast-bill-ackman-vows-to-unleash-hell-in-lawsuit-against-media-site-over-plagia">&#8216;Business Insider Is Toast:&#8217; Bill Ackman Vows To &#8216;Unleash Hell&#8217; In Lawsuit Against Media Site Over Plagiarism Claims Against Wife</a></em></p>
<p><strong>Why It's Important:</strong> The report on Axel Springer also hits on the company's relationship with people close to former President <strong>Donald Trump</strong> in years past.</p>
<p>Axel Springer worked to maintain a relationship with the Trump administration during his time in the White House.</p>
<p>The media company prides itself in trying to be neutral in politics coverage. A 2022 Washington Post <a href="https://www.washingtonpost.com/media/2022/09/06/mathias-dopfner-trump-email-axel-springer-politico/">story </a>that showed leaked emails in which Döpfner appeared to express support for the re-election of Trump, seemingly contradicting this stance. Döpfner later said he was being sarcastic.</p>
<p>"All media executives, including Mathias, take meetings and have professional relationships with business leaders, political figures and government officials who hold a wide array of political views – it's part of the job," an Axel Springer spokesperson told Semafor.</p>
<p>Axel Springer also has had a strong relationship with<strong> Richard Grenell</strong> in the past. Grenell is the former U.S. Ambassador to Germany and considered a potential Secretary of State candidate if Trump is re-elected.</p>
<p>With its past relationships with the Trump administration and potential expansion through further U.S. media acquisitions, Axel Springer may increasingly influence the landscape of American political coverage.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/news/24/02/37393818/google-faces-2-3b-lawsuit-from-european-media-over-ad-practices">Google Faces $2.3B Lawsuit from European Media Over Ad Practices</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Politics

Will Rupert Murdoch Dump The WSJ? Politico, Business Insider Owner Licks His Lips While Bill Ackman Battle Casts Huge Shadow (UPDATED)

<p>Recently listed&nbsp;<strong>Alto Neuroscience Inc</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38376753/alto-neuroscience-announces-positive-phase-1-results-for-alto-101-a-novel-pde4-inhibitor-in-develo" rel="noreferrer noopener">associated with schizophrenia (CIAS)</a>.&nbsp;</p>
<p>Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS or a patch) compared to oral administration.&nbsp;</p>
<p>The drug exposure levels achieved with the transdermal formulation were significantly greater than systemic exposure with oral administration while also reducing typical class-wide adverse events.&nbsp;</p>
<p>The company plans to initiate a proof-of-concept study evaluating ALTO-101 in patients with CIAS in the first half of 2024, with topline data expected in the second half of 2025.</p>
<p>ALTO-101 delivered transdermally resulted in significantly higher and consistent drug concentrations compared to oral administration:</p>
<ul>
<li>Area under the curve (AUC) was 62% and 170% higher on day&nbsp;1&nbsp;and day 2, respectively, for the transdermal formulation relative to oral administration (day&nbsp;1&nbsp;p=0.01; day 2 p&lt;0.001).</li>
<li>The maximum concentration (Cmax.) on day 2 of the transdermal dosing was similar to&nbsp;the Cmax&nbsp;of 1mg of orally administered ALTO-101 (27.9 ng/mL for TDS vs. 30.1 ng/mL oral).</li>
<li>Plasma concentrations for the transdermal formulation remained stable throughout the 24 hours of dosing on day 2.</li>
<li>ALTO-101 delivered transdermally resulted in substantially lower class-related adverse events typically associated with PDE4 inhibitors.</li>
<li>All adverse events reported in the study were mild, with no reported&nbsp;serious&nbsp;adverse events.&nbsp;</li>
<li>The transdermal formulation demonstrated favorable adhesion properties, and no application site reactions led to patch removal or intolerance.</li>
</ul>
<p>Upon achieving the pharmacokinetic profile for ALTO-101, MEDRx is eligible to receive a milestone payment of&nbsp;$1.5 million&nbsp;from Alto&nbsp;in cash and stock.</p>
<p><strong>William Blair</strong>&nbsp;views the update as an incremental positive as the company addresses otherwise likely development-limiting tolerability issues from one of its earlier stage programs. The analyst reiterates the Outperform rating on Alto.&nbsp;</p>
<p>Alto is in the early stages but is uniquely positioned in the neuropsychiatry drug development landscape&nbsp;with a positively biased&nbsp;risk/reward profile&nbsp;at current trading levels.</p>
<p>Data from this trial could de-risk Alto's Precision Psychiatry Platform approach with the&nbsp;next&nbsp;readout leveraging EEG-based biomarkers identified by Alto Scope in the Phase IIb trial of ALTO-300 in adjunctive MDD therapy.&nbsp;</p>
<p><strong>Price Action:</strong> ANRO shares are up 2.13% at $13.93 at the last check Tuesday.</p>
<p><em>Photo via Shutterstock</em></p>


Analyst Color

ANRO

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

Pentagon Calls On Government Of Iraq To Take All Necessary Steps To Defend U.S. Forces

<h4><strong>Key Takeaways:</strong></h4>
<ul>
<li>Fosun International&rsquo;s total debt-to-capitalization ratio stood at 50.4% at the end of last year, down 2.9 percentage points from the previous year</li>
<li>The company recently announced the sale of most of its stake in Belgian insurer Ageas, and has raised 57.3 billion yuan from similar asset sales over the past two years</li>
</ul>
<p>Li Shih Ta</p>
<p>After years of mining the globe for assets, conglomerate&nbsp;<strong>Fosun International Ltd.</strong>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/fosuf#OTC">FOSUF</a>) has shifted into a new phase as it tries to find the right balance between its large stable of myriad businesses and a suitable level of debt. In the latest of its recent spree of asset sales to reduce that debt and focus on its core areas, the company&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0414/2024041400019.pdf">announced</a>&nbsp;last week it was selling 8.19% of its stake in Belgian insurer Ageas.&nbsp;</p>
<p>&ldquo;We used to prospect and mine the world,&rdquo; said Fosun Chairman Guo Guangchang at his company&rsquo;s annual results conference late last month. &ldquo;But now we have enough good resources in areas where we have an advantage.&rdquo;</p>
<p>Fosun International&rsquo;s latest asset sale will see it sell the 8.19% in Ageas to a unit of French banking giant BNP Paribas for a total consideration of 626 million euros ($667 million) to 670 million euros. The transaction is expected to bring the company a pre-tax profit of 60 million euros to 65 million euros, and will still leave Fosun as a small shareholder in Ageas with a stake of just over 1%.</p>
<p>The deal marks Fosun&rsquo;s second sale of a major financial asset this year, following its sale of 5.6% of Banco Comercial Portugu&ecirc;s in January for 235 million euros. That sale still left Fosun with more than 20% of the bank&rsquo;s shares. Reports emerged last month that it would also like to sell that remaining stake, which is worth about 840 million euros, though no deals have been announced.</p>
<h3><strong>From Shopper To Slimmer</strong></h3>
<p>Fosun International has shifted from its former status as a &ldquo;crazy shopper&rdquo; to the current &ldquo;slim-down&rdquo; mode ever since being put on a watch list for a possible downgrade by Moody&rsquo;s in 2022. The company&rsquo;s list of other asset sales includes stakes in Nanjing Iron and Steel, Tianjin Jianlong Iron &amp; Steel and Ameritrust Group. It recovered 27.3 billion yuan in cash last year, and together with another 30 billion yuan in cash the year before that, has recovered a total of 57.3 billion yuan ($7.9 billion) in cash over the past two years.</p>
<p>The sales are making a significant dent in Fosun&rsquo;s financial burdens. The company had 211.9 billion yuan in interest-bearing debt at the end of last year, 15 billion yuan less than a year earlier. And its latest total debt-to-capitalization ratio was 50.4%, down 2.9 percentage points from a year earlier. Fosun International previously announced last August that it was no longer under pressure to repay large amounts of U.S. dollar debt in the next 12 months. As its situation improved, S&amp;P Global upgraded the company&rsquo;s outlook to &ldquo;stable&rdquo; in mid-2023.</p>
<p>The company&rsquo;s medium- and long-term debt as a percentage of total debt increased to 55% at the end of last year from 53.2% at the end of 2022. Its short-term debt, defined as that maturing within 12 months, decreased to 95.4 billion yuan from 106.3 billion yuan over that period, though the latest figure is still higher than the company&rsquo;s 92.5 billion yuan in cash at the end of last year.</p>
<h3><strong>Business Stabilizing</strong></h3>
<p>While the slim-down is making progress, it hasn&rsquo;t shown signs of ending just yet. Reuters reported last month that Fosun International was considering selling some or all of its Atlantis Sanya mega-resort as well as part of French resort operator Club Med, which are both owned by its Fosun Tourism&nbsp;affiliate. We should note that both of those earned record revenue last year and are considered important money spinners for the company, though Fosun International has yet to specifically comment on whether it might sell those assets.</p>
<p>Fosun International reported total revenue of 198.2 billion yuan last year, up 8.6% year-on-year, with a profit of 1.38 billion yuan, reversing a loss of 830 million yuan in 2022. Its four core subsidiaries Yuyuan Inc.,&nbsp;<strong>Fosun Pharma</strong>&nbsp;(2196.HK), Fosun Tourism and Fosun Insurance Portugal, all reported solid revenues, contributing 72% of its total revenue. That shows its core business are performing relatively well.</p>
<p>A report released by Citi this month said profitability of the company&rsquo;s asset portfolio has improved, leading to a narrowing of losses in its asset management segment. Citi added that most of the negative factors facing the company have been reflected in the stock price, but still lowered its target price from HK$7.10 to HK$6.30, maintaining an &ldquo;overweight&rdquo; rating.</p>
<h3><strong>Strategic Tie-Ups</strong></h3>
<p>While it may be selling assets, Fosun International has also continued making strategic moves in medicine and tourism, two areas that it considers its core focuses. Last July, Fosun Pharma signed a strategic cooperation framework agreement with Shenzhen&rsquo;s Pingshan District to build a Fosun Pharma Headquarters in South China&rsquo;s Greater Bay Area, becoming the company&rsquo;s second base outside of its home in Shanghai.</p>
<p>And last month, Fosun Pharma and seven other investors proposed setting up a 5 billion yuan biomedical fund. Earlier this month, the Shenzhen municipal government and Fosun High Technology signed a strategic cooperation framework agreement focused on strengthening cooperation in the fields of biomedicine, culture, sports and tourism, and fashion consumption in the southern Chinese boomtown next to Hong Kong.</p>
<p>In terms of tourism, Fosun Tourism Chairman Xu Xiaoliang recently revealed that he is actively planning his first &ldquo;Super Club Med&rdquo; project in Hainan with an aim of creating more world-class tourism products to promote China&rsquo;s local tourism industry.</p>
<p>After nearly two years of aggressive slimming, Fosun finally seems to have eased market concerns about its debt. Its current price-to-earnings (P/E) ratio is about 23 times, much higher than the 5.8 times for&nbsp;<strong>CK Hutchison Holdings&nbsp;</strong>(0001.HK) and the 3.3 times for<strong>&nbsp;Shanghai Industrial Holdings</strong>(0363.HK), two other conglomerates, showing the market may have regained some confidence in the company.</p>
<p>Speaking at an entrepreneur convention earlier this year in Shanghai, Guo Guangchang indicated the worst may be behind for his company. &ldquo;The difficult times are in the past, and as long as there&rsquo;s life there&rsquo;s hope,&rdquo; he said. &ldquo;After making it through such rough waters, Fosun International will be able to sail towards a brighter future.&rdquo;</p>
<p>That said, many still expect Fosun International to sell another 20 billion yuan to 30 billion yuan worth of non-core assets this year, which will further help to ease its debt load. That could give the company more breathing room in an &ldquo;asset light&rdquo; future anchored by a few core businesses.</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>
